Celgene Corp. has entered an agreement to acquire Avila Therapeutics, Inc. for $350 million in cash. The acquisition includes Avila’s AVL-292, a highly-selective Bruton’s tyrosine kinase (Btk) inhibitor, currently in Phase I development, as well as Avila’s Avilomics Platform. Avila Therapeutics is eligible to receive an additional $195 million for milestones based on development and regulatory approval of AVL-292, as well as $380 million in potential milestone payments contingent upon the devel...